A Phase 2 interventional study of bevacizumab [Avastin] and 5 FU in Neoplasms, sponsored by Hoffmann-La Roche. Completed at 27 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-22.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This 2 arm study will assess the efficacy and safety of two systemic treatments including Avastin in patients with previously-untreated progressive locally advanced/metastatic well-differentiated digestive endocrine tumors. Patients with duodeno-pancreatic tumors (arm 1) will be treated with 5FU/streptozotocin iv (5FU 400mg/m2/d D1 to D5;streptozotocin 500mg/m2/d/iv D1 to D5;D1=D42) every 6 weeks, plus Avastin 7.5mg/kg iv every 3 weeks. Patients with gastrointestinal tract tumors (arm 2) will be treated with Xeloda 1000mg/m2 po bid D1 to D14 plus Avastin 7.5mg/kg iv D1=D21 every 3 weeks. The patients will be treated with chemotherapy for a minimum of 6 months, unless there is tumor progression and/or unacceptable toxicity. The anticipated time on study treatment is until disease progression or unacceptable toxicity, and the target sample size is \<100 individuals.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 83 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: bevacizumab [Avastin] · Drug: 5 FU · Drug: Streptozotocin
Drug: bevacizumab [Avastin] · Drug: Xeloda
7.5mg/kg iv on day 1 every 3 weeks
400mg/m2/day iv on days 1-5 every 6 weeks
500mg/m2/day iv on days 1-5 every 6 weeks
1000mg/m2 po bid on days 1-14 every 3 weeks
Progression-Free Survival (PFS) - Percentage of Participants With an Event
PFS is defined as the interval between the date of start of treatment and the date of evaluation by the investigator of progressive disease or death from any cause. The progression was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) using medical imaging during the treatment period and by the investigators (confirmed by medical imaging) during the follow-up period. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of disease progression or death were censored at the date of the last visit or follow-up without progression.
Time frame: Screening, every 3 months during treatment, every 6 months during follow-up to 2 years
PFS - Time to Event
PFS is defined as the interval between the date of start of treatment and the date of evaluation by the investigator of progressive disease or death from any cause. The progression was assessed according to RECIST using medical imaging during the treatment period and by the investigators (confirmed by medical imaging) during the follow-up period. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of disease progression or death were censored at the date of the last visit or follow-up without progression. Median PFS was estimated using the Kaplan-Meier method.
Time frame: Screening, every 3 months during treatment, every 6 months during follow-up to 2 years
PFS - Percentage of Participants Estimated to be Progression Free at 12 and 24 Months
PFS is defined as the interval between the date of start of treatment and the date of evaluation by the investigator of progressive disease or death from any cause. The progression was assessed according to RECIST using medical imaging during the treatment period and by the investigators (confirmed by medical imaging) during the follow-up period. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of disease progression or death were censored at the date of the last visit or follow-up without progression.
Time frame: Screening, every 3 months during treatment, every 6 months during follow-up to 2 years
Percentage of Participants With a Response by Best Overall Response
Best overall response defined as best response recorded during the study as defined according to RECIST; performed by the investigator and by centralized review. Complete response (CR): complete disappearance of all target lesions and non-target disease. All lesions, both target and non-target, must have decreased to normal (short axis, less than \[\<\]10 millimeters \[mm\]). No new lesions. Partial response (PR): greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter (LD) was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. Stable disease (SD): not qualifying for CR, PR, or Progressive Disease (PD). PD: at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.
Time frame: Screening, every 3 months during treatment, every 6 months during follow-up to 2 years
Duration of Overall Response (OR) - Percentage of Participants With an Event
Determined only for those participants with an overall response (CR or PR) and was defined as the time interval between the response (CR or PR) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression.
Time frame: Screening, every 3 months during treatment, every 6 months during follow-up to 2 years
Duration of OR - Time to Event
Determined only for those participants with an overall response (CR or PR) and was defined as the time interval between the response (CR or PR) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression. Median duration of OR was estimated using the Kaplan-Meier method.
Time frame: Screening, every 3 months during treatment, every 6 months during follow-up to 2 years
Duration of OR - Percentage of Participants With Sustained Response at 12 and 24 Months
Duration of OR was determined only for those participants with an overall response of CR or PR and was defined as the time interval between the response (CR or PR) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression.
Time frame: Screening, every 3 months during treatment, every 6 months during follow-up to 2 years
Duration of Overall Disease Control (ODC) - Percentage of Participants With an Event
Determined only for those participants with overall disease control (CR, PR or SD per RECIST) and was defined as the time interval between the first occurrence of disease control (CR, PR or SD) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression.
Time frame: Screening, every 3 months during treatment, every 6 months during follow-up to 2 years
Duration of ODC - Time to Event
Determined only for those participants with overall control disease (CR, PR, or SD per RECIST) and was defined as the time interval between the first occurrence of disease control (CR, PR or SD) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression. Median time to event was estimated using the Kaplan-Meier method.
Time frame: Screening, every 3 months during treatment, every 6 months during follow-up to 2 years
Duration of ODC - Percentage of Participants Maintaining Disease Control at 12 and 24 Months
Duration of ODC was determined only for those participants with overall control disease (CR, PR, or SD per RECIST) and was defined as the time interval between the first occurrence of disease control (CR, PR, or SD) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression.
Time frame: Screening, every 3 months during treatment, every 6 months during follow-up to 2 years
Overall Survival (OS) - Percentage of Participants With an Event
OS was defined as the time from the first treatment administration to death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation. Data for participants who were alive at the end of the study were censored at the date of last visit.
Time frame: Screening, Day 1 of every cycle during treatment, every 6 months during follow-up to 2 years
OS - Time to Event
OS was defined as the time from the first treatment administration to death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation. Data for participants who were alive at the end of the study were censored at the date of last visit. Median OS was estimated using the Kaplan-Meier method.
Time frame: Screening, Day 1 of every cycle during treatment, every 6 months during follow-up to 2 years
OS - Percentage of Participants Surviving at 12 and 24 Months
OS was defined as the time from the first treatment administration to death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation. Data for participants who were alive at the end of the study were censored at the date of last visit.
Time frame: Screening, Day 1 of every cycle during treatment, every 6 months during follow-up to 2 years
Global Health Status as Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - C30 (EORTC QLQ-C30)
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores were averaged and transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.
Time frame: Screening, every 3 months during treatment
Percentage of Participants With Change From Baseline in Global Health Status by EORTC QLQ-C30 Improvement Category
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms. Changes from baseline were categorized as follows: Very much worsening (less than \[\<\]-20); Moderate worsening (greater than or equal to \[≥\]-20 to \<-10); Little worsening (≥-10 to \<-5); No change (≥-5 to less than or equal to \[≤\]5); Little improvement (\>5 to ≤10); Moderate improvement (\>10 to ≤20); and Very much improved (\>20).
Time frame: Screening, every 3 months during treatment
EORTC QLQ-C30 Functional and Symptom Scale Scores
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores averaged, transformed to 0-100 scale; for functional scores, a higher score represents a better level of functioning. For symptom scale scores a higher level represents a more severe level of symptoms.
Time frame: Screening, every 3 months during treatment
| Milestone | Bevacizumab + 5-fluorouracil (5-FU) + Streptozocin | Bevacizumab + Capecitabine |
|---|---|---|
| Started | 34 | 49 |
| Completed | 30 | 41 |
| Not completed | 4 | 8 |
| Withdrew: Death | 3 | 8 |
| Withdrew: Investigator's decision (progression) | 1 | 0 |
PFS is defined as the interval between the date of start of treatment and the date of evaluation by the investigator of progressive disease or death from any cause. The progression was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) using medical imaging during the treatment period and by the investigators (confirmed by medical imaging) during the follow-up period. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of disease progression or death were censored at the date of the last visit or follow-up without progression.
| percentage of participants | Bevacizumab + 5-FU + Streptozocin | Bevacizumab + Capecitabine |
|---|---|---|
| Progression-Free Survival (PFS) - Percentage of Participants With an Event | 52.9 | 53.1 |
Best overall response defined as best response recorded during the study as defined according to RECIST; performed by the investigator and by centralized review. Complete response (CR): complete disappearance of all target lesions and non-target disease. All lesions, both target and non-target, must have decreased to normal (short axis, less than \[\<\]10 millimeters \[mm\]). No new lesions. Partial response (PR): greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter (LD) was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. Stable disease (SD): not qualifying for CR, PR, or Progressive Disease (PD). PD: at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.
| percentage of participants | Bevacizumab + 5-FU + Streptozocin | Bevacizumab + Capecitabine |
|---|---|---|
| PR (Investigator) | 55.9 (39.2 to 72.6) | 18.4 (7.5 to 29.2) |
| PR (Centralized review) | 51.5 (34.5 to 68.6) | 12.5 (3.1 to 21.9) |
| SD (Investigator) | 44.1 (27.4 to 60.8) | 69.4 (56.5 to 82.3) |
| SD (Centralized review) | 48.5 (31.4 to 65.5) | 81.3 (70.2 to 92.3) |
| PD (Investigator) | 0 (0 to 0) | 8.2 (0.5 to 15.8) |
| PD (Centralized review) | 0 (0 to 0) | 0 (0 to 0) |
| Not evaluable (Investigator) | 0 (0 to 0) | 4.1 (0.0 to 9.6) |
| Not evaluable (Centralized review) | 0 (0 to 0) | 6.3 (0.0 to 13.1) |
Determined only for those participants with an overall response (CR or PR) and was defined as the time interval between the response (CR or PR) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression.
| percentage of participants | Bevacizumab + 5-FU + Streptozocin | Bevacizumab + Capecitabine |
|---|---|---|
| Duration of Overall Response (OR) - Percentage of Participants With an Event | 42.1 | 22.2 |
PFS is defined as the interval between the date of start of treatment and the date of evaluation by the investigator of progressive disease or death from any cause. The progression was assessed according to RECIST using medical imaging during the treatment period and by the investigators (confirmed by medical imaging) during the follow-up period. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of disease progression or death were censored at the date of the last visit or follow-up without progression. Median PFS was estimated using the Kaplan-Meier method.
| months | Bevacizumab + 5-FU + Streptozocin | Bevacizumab + Capecitabine |
|---|---|---|
| PFS - Time to Event | 23.7 (13.1 to NA) | 23.4 (13.2 to NA) |
PFS is defined as the interval between the date of start of treatment and the date of evaluation by the investigator of progressive disease or death from any cause. The progression was assessed according to RECIST using medical imaging during the treatment period and by the investigators (confirmed by medical imaging) during the follow-up period. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of disease progression or death were censored at the date of the last visit or follow-up without progression.
| percentage of participants | Bevacizumab + 5-FU + Streptozocin | Bevacizumab + Capecitabine |
|---|---|---|
| 12 months | 76 | 65 |
| 24 months | 50 | 48 |
Determined only for those participants with an overall response (CR or PR) and was defined as the time interval between the response (CR or PR) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression. Median duration of OR was estimated using the Kaplan-Meier method.
| months | Bevacizumab + 5-FU + Streptozocin | Bevacizumab + Capecitabine |
|---|---|---|
| Duration of OR - Time to Event | NA (11.2 to NA) | NA (3.2 to NA) |
Duration of OR was determined only for those participants with an overall response of CR or PR and was defined as the time interval between the response (CR or PR) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression.
| percentage of participants | Bevacizumab + 5-FU + Streptozocin | Bevacizumab + Capecitabine |
|---|---|---|
| 12 months | 74 | 70 |
| 24 months | 55 | NA |
Determined only for those participants with overall disease control (CR, PR or SD per RECIST) and was defined as the time interval between the first occurrence of disease control (CR, PR or SD) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression.
| percentage of participants | Bevacizumab + 5-FU + Streptozocin | Bevacizumab + Capecitabine |
|---|---|---|
| Duration of Overall Disease Control (ODC) - Percentage of Participants With an Event | 52.9 | 46.5 |
Determined only for those participants with overall control disease (CR, PR, or SD per RECIST) and was defined as the time interval between the first occurrence of disease control (CR, PR or SD) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression. Median time to event was estimated using the Kaplan-Meier method.
| months | Bevacizumab + 5-FU + Streptozocin | Bevacizumab + Capecitabine |
|---|---|---|
| Duration of ODC - Time to Event | 22.3 (11.9 to NA) | 23.4 (15.1 to NA) |
Duration of ODC was determined only for those participants with overall control disease (CR, PR, or SD per RECIST) and was defined as the time interval between the first occurrence of disease control (CR, PR, or SD) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression.
| percentage of participants | Bevacizumab + 5-FU + Streptozocin | Bevacizumab + Capecitabine |
|---|---|---|
| 12 months | 68 | 72 |
| 24 months | 42 | NA |
OS was defined as the time from the first treatment administration to death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation. Data for participants who were alive at the end of the study were censored at the date of last visit.
| percentage of participants | Bevacizumab + 5-FU + Streptozocin | Bevacizumab + Capecitabine |
|---|---|---|
| Overall Survival (OS) - Percentage of Participants With an Event | 14.7 | 16.3 |
OS was defined as the time from the first treatment administration to death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation. Data for participants who were alive at the end of the study were censored at the date of last visit. Median OS was estimated using the Kaplan-Meier method.
| months | Bevacizumab + 5-FU + Streptozocin | Bevacizumab + Capecitabine |
|---|---|---|
| OS - Time to Event | NA (27 to NA) | NA (NA to NA) |
OS was defined as the time from the first treatment administration to death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation. Data for participants who were alive at the end of the study were censored at the date of last visit.
| percentage of participants | Bevacizumab + 5-FU + Streptozocin | Bevacizumab + Capecitabine |
|---|---|---|
| 12 months | 94 | 88 |
| 24 months | 88 | 85 |
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores were averaged and transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.
| units on a scale | Bevacizumab + 5-FU + Streptozocin | Bevacizumab + Capecitabine |
|---|---|---|
| Baseline (n=29,40) | 65.23 ± 23.89 | 65.42 ± 20.02 |
| 3 months (n=20,32) | 65.83 ± 19.48 | 57.03 ± 22.41 |
| 6 months (n=20,24) | 60.00 ± 21.90 | 66.32 ± 21.35 |
| 12 months (n=13,14) | 66.03 ± 17.83 | 72.62 ± 19.46 |
| End of treatment (n=13,23) | 64.74 ± 23.36 | 57.97 ± 28.48 |
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms. Changes from baseline were categorized as follows: Very much worsening (less than \[\<\]-20); Moderate worsening (greater than or equal to \[≥\]-20 to \<-10); Little worsening (≥-10 to \<-5); No change (≥-5 to less than or equal to \[≤\]5); Little improvement (\>5 to ≤10); Moderate improvement (\>10 to ≤20); and Very much improved (\>20).
| percentage of participants | Bevacizumab + 5-FU + Streptozocin | Bevacizumab + Capecitabine |
|---|---|---|
| 3 months, Very much worsening (n=20,29) | 10.0 | 17.2 |
| 3 months, Moderate worsening (n=20,29) | 10.0 | 24.1 |
| 3 months, Little worsening (n=20,29) | 10.0 | 17.2 |
| 3 months, No change (n=20,29) | 40.0 | 24.1 |
| 3 months, Little improving (n=20,29) | 5.0 | 3.4 |
| 3 months, Moderate Improving (n=20,29) | 15.0 | 3.4 |
| 3 months, Very much improving (n=20,29) | 10.0 | 10.3 |
| 6 months, Very much worsening (n=20,22) | 15.0 | 22.7 |
| 6 months, Moderate worsening (n=20,22) | 10.0 | 18.2 |
| 6 months, Little worsening (n=20,22) | 5.0 | 0 |
| 6 months, No change (n=20,22) | 35.0 | 31.8 |
| 6 months, Little improving (n=20,22) | 10.0 | 13.6 |
| 6 months, Moderate Improving (n=20,22) | 15.0 | 0 |
| 6 months, Very much improving (n=20,22) | 10.0 | 13.6 |
| 12 months, Very much worsening (n=12,13) | 8.3 | 0 |
| 12 months, Moderate worsening (n=12,13) | 8.3 | 15.4 |
| 12 months - Little worsening (n=12,13) | 33.3 | 15.4 |
| 12 months, No change (n=12,13) | 25.0 | 38.5 |
| 12 months, Little improving (n=12,13) | 8.3 | 7.7 |
| 12 months, Moderate Improving (n=12,13) | 16.7 | 15.4 |
| 12 months, Very much improving (n=12,13) | 0 | 7.7 |
| End of treatment, Very much worsening (n=13,20) | 15.4 | 15.0 |
| End of treatment, Moderate worsening (n=13,20) | 30.8 | 5.0 |
| End of treatment, Little worsening (n=13,20) | 0 | 10.0 |
| End of treatment, No change (n=13,20) | 15.4 | 45.0 |
| End of treatment, Little improving (n=13,20) | 15.4 | 10.0 |
| End of treatment, Moderate Improving (n=13,20) | 15.4 | 5.0 |
| End of treatment, Very much improving (n=13,20) | 7.7 | 10.0 |
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores averaged, transformed to 0-100 scale; for functional scores, a higher score represents a better level of functioning. For symptom scale scores a higher level represents a more severe level of symptoms.
| units on a scale | Bevacizumab + 5-FU + Streptozocin | Bevacizumab + Capecitabine |
|---|---|---|
| Physical functioning, Baseline (n=30,43) | 90.44 ± 13.30 | 87.71 ± 14.88 |
| Physical functioning, 3 months (n=22,33) | 89.32 ± 12.77 | 75.35 ± 24.07 |
| Physical functioning, 6 months (n=21,24) | 81.98 ± 19.75 | 82.50 ± 18.21 |
| Physical functioning, End of Treatment (n=13,24) | 82.82 ± 20.21 | 79.44 ± 19.85 |
| Role functioning, Baseline (n=30,43) | 82.22 ± 27.31 | 83.33 ± 25.46 |
| Role functioning, 3 months (n=22,33) | 85.61 ± 21.39 | 62.12 ± 33.66 |
| Role functioning, 6 months (n=21,24) | 75.40 ± 29.16 | 70.83 ± 28.34 |
| Role functioning, End of Treatment (n=13,24) | 78.21 ± 32.90 | 72.92 ± 29.00 |
| Emotional functioning, Baseline (n=30,42) | 71.94 ± 28.32 | 71.89 ± 20.50 |
| Emotional functioning, 3 months (n=21,33) | 81.48 ± 20.53 | 76.01 ± 24.27 |
| Emotional functioning, 6 months (n=21,24) | 72.62 ± 28.28 | 76.04 ± 26.27 |
| Emotional functioning, End of Treatment (n=13,24) | 77.56 ± 23.17 | 73.61 ± 24.04 |
| Cognitive functioning, Baseline (n=30,42) | 86.67 ± 18.26 | 87.30 ± 16.38 |
| Cognitive functioning, 3 months (n=22,33) | 89.39 ± 15.04 | 83.84 ± 21.03 |
| Cognitive functioning, 6 months (n=21,24) | 83.33 ± 21.08 | 82.64 ± 18.04 |
| Cognitive functioning, End of Treatment (n=13,24) | 83.33 ± 22.57 | 81.94 ± 25.97 |
| Social functioning, Baseline (n=30,41) | 86.11 ± 21.48 | 87.40 ± 20.34 |
| Social functioning, 3 months (n=22,33) | 89.39 ± 17.48 | 75.76 ± 27.35 |
| Social functioning, 6 months (n=21,24) | 81.75 ± 26.30 | 83.33 ± 21.42 |
| Social functioning, End of Treatment (n=13,24) | 84.62 ± 24.96 | 81.94 ± 21.93 |
| Fatigue, Baseline (n=30,42) | 26.30 ± 23.61 | 27.25 ± 21.70 |
| Fatigue, 3 months (n=21,33) | 27.78 ± 23.70 | 43.10 ± 31.76 |
| Fatigue, 6 months (n=20,24) | 36.67 ± 29.09 | 37.96 ± 23.61 |
| Fatigue, End of Treatment (n=13,24) | 34.19 ± 28.85 | 34.49 ± 32.93 |
| Nausea and vomiting, Baseline (n=30,42) | 6.67 ± 14.91 | 2.78 ± 7.29 |
| Nausea and vomiting, 3 months (n=22,33) | 10.61 ± 14.13 | 9.60 ± 16.15 |
| Nausea and vomiting, 6 months (n=21,24) | 8.73 ± 17.97 | 7.64 ± 12.98 |
| Nausea and vomiting, End of Treatment (n=13,24) | 10.26 ± 19.88 | 6.25 ± 14.59 |
| Pain, Baseline (n=30,43) | 14.44 ± 19.44 | 21.71 ± 27.83 |
| Pain, 3 months (n=22,33) | 12.88 ± 18.50 | 18.18 ± 25.47 |
| Pain, 6 months (n=21,24) | 23.02 ± 31.83 | 17.36 ± 19.95 |
| Pain, End of Treatment (n=13,24) | 20.51 ± 28.18 | 26.39 ± 32.94 |
| Dyspnea, Baseline (n=30,43) | 16.67 ± 25.89 | 16.28 ± 25.59 |
| Dyspnea, 3 months (n=21,33) | 12.70 ± 19.65 | 30.30 ± 32.66 |
| Dyspnea, 6 months (n=21,23) | 19.05 ± 24.88 | 23.19 ± 29.19 |
| Dyspnea, End of Treatment (n=13,24) | 20.51 ± 28.99 | 23.61 ± 30.26 |
| Insomnia, Baseline (n=30,43) | 24.44 ± 27.59 | 24.03 ± 24.48 |
| Insomnia, 3 months (n=21,33) | 20.63 ± 22.30 | 27.27 ± 30.57 |
| Insomnia, 6 months (n=21,24) | 33.33 ± 34.96 | 29.17 ± 30.00 |
| Insomnia, End of Treatment (n=13,24) | 23.08 ± 25.04 | 30.56 ± 33.93 |
| Appetite loss, Baseline (n=29,42) | 12.64 ± 16.46 | 8.73 ± 20.90 |
| Appetite loss, 3 months (n=22,33) | 7.58 ± 14.30 | 20.20 ± 24.92 |
| Appetite loss, 6 months (n=21,24) | 15.87 ± 27.12 | 25.00 ± 26.47 |
| Appetite loss, End of Treatment (n=13,24) | 12.82 ± 28.99 | 25.00 ± 32.97 |
| Constipation, Baseline (n=27,40) | 4.94 ± 15.20 | 10.00 ± 21.62 |
| Constipation, 3 months (n=21,33) | 15.87 ± 27.12 | 7.07 ± 18.18 |
| Constipation, 6 months (n=21,23) | 17.46 ± 27.12 | 11.59 ± 21.58 |
| Constipation, End of Treatment (n=13,24) | 12.82 ± 21.68 | 13.89 ± 25.85 |
| Diarrhea, Baseline (n=30,41) | 13.33 ± 24.13 | 37.40 ± 31.79 |
| Diarrhea, 3 months (n=22,32) | 9.09 ± 21.04 | 45.83 ± 34.65 |
| Diarrhea, 6 months (n=21,23) | 6.35 ± 17.06 | 43.48 ± 30.87 |
| Diarrhea, End of Treatment (n=12,22) | 2.78 ± 9.62 | 28.79 ± 31.36 |
| Financial difficulties, Baseline (n=30,413) | 14.44 ± 25.80 | 8.13 ± 17.92 |
| Financial difficulties, 3 months (n=22,33) | 9.09 ± 15.19 | 6.06 ± 15.49 |
| Financial difficulties, 6 months (n=21,23) | 15.87 ± 24.99 | 2.90 ± 9.60 |
| Financial difficulties, End of treatment (n=13,24) | 17.95 ± 25.88 | 4.17 ± 14.95 |
Collected over Adverse events (AEs) were collected from the date of first dose of study medication until 28 days after the last dose of study medication. Related serious AEs and AEs of special interest (AESIs) were recorded during follow-up.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bevacizumab + 5-FU + Streptozocin | — | 11/34 (32.4%) | 34/34 (100%) |
| Bevacizumab + Capecitabine | — | 13/49 (26.5%) | 49/49 (100%) |
| Event | Bevacizumab + 5-FU + Streptozocin | Bevacizumab + Capecitabine |
|---|---|---|
| PyrexiaGeneral disorders | 3/34 | 0/49 |
| Abdominal pain upperGastrointestinal disorders | 2/34 | 0/49 |
| Gastrointestinal hemorrhageGastrointestinal disorders | 2/34 | 0/49 |
| HypoglycaemiaMetabolism and nutrition disorders | 2/34 | 0/49 |
| Abdominal painGastrointestinal disorders | 0/34 | 2/49 |
| Intestinal obstructionGastrointestinal disorders | 0/34 | 2/49 |
| General physical health deteriorationGeneral disorders | 0/34 | 2/49 |
| Influenza like illnessGeneral disorders | 1/34 | 0/49 |
| Post-procedural sepsisInfections and infestations | 1/34 | 0/49 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/34 | 0/49 |
| Event | Bevacizumab + 5-FU + Streptozocin | Bevacizumab + Capecitabine |
|---|---|---|
| NauseaGastrointestinal disorders | 24/34 | 24/49 |
| AstheniaGeneral disorders | 23/34 | 28/49 |
| DiarrhoeaGastrointestinal disorders | 12/34 | 32/49 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 6/34 | 31/49 |
| ConstipationGastrointestinal disorders | 19/34 | 9/49 |
| Mucosal inflammationGeneral disorders | 14/34 | 17/49 |
| Abdominal painGastrointestinal disorders | 13/34 | 12/49 |
| HeadacheNervous system disorders | 13/34 | 14/49 |
| Abdominal pain upperGastrointestinal disorders | 11/34 | 11/49 |
| VomitingGastrointestinal disorders | 11/34 | 7/49 |
Intent-to-treat (ITT) population: all participants who received at least 1 dose of treatment.
| Age, Continuous(years) | Bevacizumab + 5-FU + Streptozocin | Bevacizumab + Capecitabine | Total |
|---|---|---|---|
| Mean | 55.93 ± 10.63 | 61.64 ± 9.20 | 59.29 ± 10.15 |
| Sex: Female, Male(Participants) | Bevacizumab + 5-FU + Streptozocin | Bevacizumab + Capecitabine | Total |
|---|---|---|---|
| Female | 12 | 23 | 35 |
| Male | 22 | 26 | 48 |
The record gives a start of Jul 2007, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluorouracil · Streptozocin · Capecitabine